Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,400,522
  • Shares Outstanding, K 68,154
  • Annual Sales, $ 57,990 K
  • Annual Income, $ -134,230 K
  • 60-Month Beta 2.05
  • Price/Sales 104.18
  • Price/Cash Flow N/A
  • Price/Book 10.98
Trade NTLA with:

Options Overview

Details
  • Implied Volatility 125.42%
  • Historical Volatility 60.37%
  • IV Percentile 95%
  • IV Rank 80.60%
  • IV High 142.93% on 12/21/20
  • IV Low 52.70% on 08/20/20
  • Put/Call Vol Ratio 3.41
  • Today's Volume 3,872
  • Volume Avg (30-Day) 1,780
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 40,614
  • Open Int (30-Day) 30,216

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.61
  • Number of Estimates 9
  • High Estimate -0.13
  • Low Estimate -0.77
  • Prior Year -0.61
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.67 +22.90%
on 05/19/21
89.71 -14.15%
on 06/15/21
+10.33 (+15.49%)
since 05/17/21
3-Month
54.09 +42.39%
on 03/25/21
89.71 -14.15%
on 06/15/21
+10.00 (+14.92%)
since 03/17/21
52-Week
16.54 +365.66%
on 09/04/20
92.00 -16.28%
on 01/15/21
+56.22 (+270.29%)
since 06/17/20

Most Recent Stories

More News
CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data

CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.

VRTX : 188.36 (+0.46%)
EDIT : 36.16 (+3.31%)
NTLA : 76.50 (-3.46%)
CRSP : 127.27 (+2.71%)
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -4.55% and -23.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?...

NTLA : 76.50 (-3.46%)
Analysts Estimate Intellia Therapeutics, Inc. (NTLA) to Report a Decline in Earnings: What to Look Out for

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NTLA : 76.50 (-3.46%)
Stocks Pause as Big Tech Bonanza Begins

Stocks Pause as Big Tech Bonanza Begins

RAIL : 5.44 (-2.68%)
CAAP : 5.28 (-0.38%)
RYAM : 7.12 (-7.77%)
MAN : 117.05 (-4.07%)
AA : 33.58 (-5.03%)
ASIX : 28.15 (-4.09%)
FHB : 28.03 (-5.56%)
SAVA : 78.60 (-2.08%)
NVAX : 179.89 (+2.07%)
GCI : 5.61 (-2.77%)
ARLO : 7.37 (+4.10%)
USFD : 36.84 (-2.28%)
SQ : 236.13 (+4.90%)
VFF : 10.51 (+1.74%)
NOW : 530.40 (+3.98%)
ABUS : 3.26 (+1.24%)
MRNA : 202.47 (+2.34%)
NTLA : 76.50 (-3.46%)
CSCO : 53.13 (-0.64%)
WMMVY : 31.0550 (-1.48%)
WLK : 93.95 (-4.29%)
ARMK : 37.42 (-0.21%)
TAL : 20.62 (-13.98%)
GOOG : 2,527.42 (+0.54%)
MSFT : 260.90 (+1.37%)
AAPL : 131.79 (+1.26%)
FB : 336.51 (+1.64%)
QCOM : 135.35 (+0.30%)
BA : 239.22 (-1.26%)
SHOP : 1,449.27 (+6.07%)
F : 14.77 (-1.66%)
EBAY : 65.33 (-1.15%)
Record Closes for NASDAQ, S&P to Begin Big Tech Week

Record Closes for NASDAQ, S&P to Begin Big Tech Week

PRFT : 79.18 (+1.42%)
SNA : 215.13 (-3.81%)
ENPH : 161.99 (+6.56%)
MPC : 60.96 (-3.67%)
DOW : 63.54 (-3.13%)
DB : 13.40 (-2.55%)
QRVO : 181.33 (-0.21%)
CHWY : 77.67 (+0.61%)
UPLD : 41.95 (-0.73%)
UFS : 54.00 (-0.11%)
THC : 68.63 (+2.79%)
X : 23.82 (-7.67%)
SBSW : 16.33 (-6.47%)
JEF : 30.16 (-5.13%)
OLN : 44.94 (-5.77%)
CLFD : 34.97 (-1.24%)
AXSM : 66.54 (+1.40%)
NTLA : 76.50 (-3.46%)
QURE : 34.50 (+0.17%)
TSLA : 616.60 (+1.94%)
GOOG : 2,527.42 (+0.54%)
MSFT : 260.90 (+1.37%)
UPS : 198.05 (-1.18%)
SBUX : 111.39 (+0.03%)
AAPL : 131.79 (+1.26%)
FB : 336.51 (+1.64%)
AMZN : 3,489.24 (+2.17%)
V : 232.15 (+1.11%)
LLY : 222.21 (+0.66%)
TXN : 187.65 (-0.04%)
Vertex (VRTX) Ups Investment in CRISPR Gene Therapy Partnership

Vertex (VRTX) to lead CRISPR Therapeutics for manufacture and commercialization of gene-editing therapy CTX001 which is being developed for treating SCD and TDT.

VRTX : 188.36 (+0.46%)
EDIT : 36.16 (+3.31%)
NTLA : 76.50 (-3.46%)
CRSP : 127.27 (+2.71%)
Strong Start to 2021 as Stocks Rise in Q1

Strong Start to 2021 as Stocks Rise in Q1

AA : 33.58 (-5.03%)
JO : 42.36 (-2.96%)
VIRT : 29.39 (+1.66%)
LAC : 13.60 (-1.09%)
NVDA : 746.29 (+4.76%)
TWST : 113.45 (+6.07%)
NTLA : 76.50 (-3.46%)
MRNA : 202.47 (+2.34%)
FB : 336.51 (+1.64%)
AAPL : 131.79 (+1.26%)
AMZN : 3,489.24 (+2.17%)
NFLX : 498.34 (+1.20%)
TSLA : 616.60 (+1.94%)
MSFT : 260.90 (+1.37%)
Intellia (NTLA) Miss Earnings & Revenues Estimates in Q4

Intellia (NTLA) miss earnings and revenues estimates in the fourth quarter of 2020. Stock up.

NTLA : 76.50 (-3.46%)
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

Style Box ETF report for FYC

FYC : 72.03 (-1.00%)
PLUG : 29.85 (+0.67%)
HOME : 36.76 (unch)
IWO : 303.78 (+0.01%)
NTLA : 76.50 (-3.46%)
VBK : 282.84 (+0.22%)
Will Intellia Therapeutics, Inc. (NTLA) Report Negative Q4 Earnings? What You Should Know

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NTLA : 76.50 (-3.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with...

See More

Key Turning Points

3rd Resistance Point 100.87
2nd Resistance Point 94.93
1st Resistance Point 87.09
Last Price 76.50
1st Support Level 73.31
2nd Support Level 67.37
3rd Support Level 59.53

See More

52-Week High 92.00
Last Price 76.50
Fibonacci 61.8% 63.17
Fibonacci 50% 54.27
Fibonacci 38.2% 45.37
52-Week Low 16.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar